METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

Ming-Shi Chang

METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

貢獻的翻譯標題: METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

Ming-Shi Chang (Inventor)

生物化學暨分子生物學研究所

研究成果: Patent

摘要

Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

貢獻的翻譯標題	METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES
原文	English
專利號	9127066
出版狀態	Published - 1800

UN SDG

此研究成果有助於以下永續發展目標

引用此

@misc{7563c45ec4ee42d08cb36eaa977735ed,

title = "METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES",

abstract = "Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.",

author = "Ming-Shi Chang",

year = "1800",

language = "English",

type = "Patent",

note = "9127066",

}

TY - PAT

T1 - METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

AU - Chang, Ming-Shi

PY - 1800

Y1 - 1800

N2 - Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

AB - Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.

M3 - Patent

M1 - 9127066

ER -

METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES

摘要

UN SDG

指紋

引用此